APPLICANT(S): LEWKOWICZ, Shlomo et al.

SERIAL NO.:

10/536,982

FILED:

May 31, 2005

Page 2

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all versions, and listings, of claims in this application.

Listing of Claims:

1-23. (**Canceled**)

24. (Previously Presented) A method of imaging diagnostic information on the GI tract, the method comprising:

administering to a patient an ingestible imaging capsule;

administering to a patient a composition comprising a fluorescent dye;

flashing illumination within the GI tract, thereby providing a light period and a dark period;

obtaining a fluorescent image of the GI tract tissue during the dark period on an image sensor within said ingestible imaging capsule; and

wirelessly transmitting image data from the ingestible imaging capsule.

- 25. (Previously Presented) The method of claim 24 comprising obtaining, on an image sensor within the ingestible capsule, a real image of the tissue during the light period.
- 26. (Previously Presented) The method of claim 25 comprising obtaining the fluorescent image and the real image on the same image sensor.
- 27. (Previously Presented) The method of claim 24 wherein flashing comprises alternately illuminating with white light.
- 28. (Canceled).
- 29. (Previously Presented) The method of claim 24 comprising focusing light remitted from the GI tract tissue onto an image sensor within the ingestible capsule.
- 30. (Previously Presented) The method of claim 24 wherein flashing comprises alternately illuminating with monochromatic light and white light.

APPLICANT(S): LEWKOWICZ, Shlomo et al.

SERIAL NO.:

10/536,982 May 31, 2005

FILED: Page 3

31. (Previously Presented) The method of claim 25 comprising processing the real image and the fluorescent image to obtain diagnostic information.

32-34. (Canceled)

35. (Currently Amended) A method comprising:

staining cells of an endo-luminal wall;

administering to a patient an in-vivo imaging capsule;

activating illumination of the in-vivo imaging capsule in a flashing mode <u>having</u> alternating light and dark periods; and

capturing light remitted <u>during the flashing mode</u> from said cells onto a light detector within the in-vivo imaging capsule.

- 36. (**Previously Presented**) The method as in claim 35, wherein said illumination comprises a polychromatic illumination and a monochromatic illumination.
- 37. (**Previously Presented**) The method as in claim 35, wherein said capturing comprises capturing a real image and a fluorescent image.
- 38. (Previously Presented) The method according to claim 24, wherein said composition administered further comprises an antibody to an antigenic determinant associated with GI cancer.
- 39. (Previously Presented) The method according to claim 38, wherein said antibody is specific to an antigenic determinant selected from a group consisting of: CA19 9 and CEA.
- 40. (Previously Presented) The method according to claim 24, wherein said composition comprises an antigenic determinant with affinity to antibodies associated with GI cancer.
- 41. (Previously Presented) The method according to claim 40, wherein said antigenic determinant is Gastric Mucin.
- 42. (Previously Presented) The method according to claim 24, comprising the step of washing the GI tract tissue, prior to administering a composition.
- 43. (Previously Presented) The method according to claim 24, further comprising the step of washing the GI tract tissue from excess of fluorescent dye, prior to administering the ingestible imaging capsule.

 $APPLICANT(S){:}\quad LEWKOWICZ,\, Shlomo\,\,et\,\,al.$

SERIAL NO.: 10/536,982 FILED: May 31, 2005

Page 4

44. (**Previously Presented**) The method according to claim 35, further comprising the step of washing the endo-luminal cells from excess of stain, prior to administering the in-vivo imaging capsule.